Dmitry Kravchenko: Earlier-Line CAR-T – A Translational and Development Inflection Point
Dmitry Kravchenko, Oncologist, Medical Monitor at R-Pharm, posted on LinkedIn:
”Earlier-Line CAR-T: A Translational and Development Inflection Point
The push for CAR-T in 1L/2L therapy is inevitable. But as a strategy, it’s incomplete without a parallel evolution in our development paradigm.
This shift demands a strategic pivot in how we define success:
Beyond OS: In earlier lines, overall survival is confounded by subsequent therapies. The new pivotal endpoints must be translational surrogates for cure: e.g., sustained MRD negativity, durable CR rates, and novel biomarkers (e.g., CAR-T persistence/phenotype) that predict long-term benefit.
The Long-Term Risk-Benefit Calculus: Introducing potent cellular therapy to treatment-naïve patients changes the risk landscape. The long-term sequelae of CRS/ICANS and persistent immunologic effects could impact eligibility for future therapies. Our development plans must prospectively model this entire journey, not just the PFS curve.
The opportunity is monumental, but capturing it requires a First-in-Human (FIH) and early-phase mindset: designing trials that are not just dose-finding, but deeply biomarker-driven, with integrated PROs and long-term safety to truly understand the therapeutic profile.
How we redesign development to prove its transformative value?”
Stay updated with Hemostasis Today.
-
May 23, 2026, 03:55WFH Initiative Brings Hope to the Hemophilia Community in India
-
May 23, 2026, 03:47Satyam Arora: Welcoming the New ISBT Board for the 2026 Term
-
May 23, 2026, 03:33Brig Tathagata Chatterjee: Connecting With World Leaders in Hematology at ISH Congress
-
May 23, 2026, 03:18Mathangi Kumar: Dental Management Strategies for Congenital Hemophilia
-
May 23, 2026, 03:02Maitri Vaishnav: Anatomical Variability and Surgical Relevance of Corona Mortis
-
May 23, 2026, 02:26Muhammad Hashim: When the Blood Smear Told a Different Story Behind a ‘Critical’ Platelet Count
-
May 23, 2026, 02:20Augustina Isioma Ikusemoro: Understanding One of the Most Common and Preventable Transfusion Reactions
-
May 23, 2026, 02:15What’s Your Advice for the Newly Diagnosed? – ITP Support Association
-
May 23, 2026, 02:08Rob Maloney: When You Stop Building Only a Career and Start Building a Life of Significance